Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care JournalsDavid J. Lederer, Jean‐Louis Vincent, Scott C. Bell et al.|Annals of the American Thoracic Society|2018Cited by 723
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael Boyle, David M. Rodman, Scott C. Bell et al.|The Lancet Respiratory Medicine|2014Cited by 442
Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care JournalsDaniel E. Leisman, David M. Maslove, Michael O. Harhay et al.|Critical Care Medicine|2020Cited by 285
Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trialShawn D. Aaron, Noni E. MacDonald, Alphonse Jeanneret et al.|The Lancet|2005Cited by 238
Antibiotic Susceptibilities of <i>Pseudomonas aeruginosa</i> Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm ConditionsDominic Hill, Colin Harbour, Barbara Rose et al.|Journal of Clinical Microbiology|2005Cited by 216